Role of Microparticles in Covid-19 Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

189 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-02

Study Completion Date

2021-10-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Among the distinctive features of Covid-19, numerous reports have stressed the importance of vascular damages associated with coagulopathy onset. Microparticles (MPs) shed by apoptotic/stimulated cells are reliable markers of vascular damage released upon pro-inflammatory conditions and behave as active participants in the early steps of clot formation. In addition, MPs carry ACE1 and ACE2, the cell-entry receptor for SARS-Cov2 in the vasculature and up-regulate ACE1 expression in neighbouring endothelial cells. This may contribute to unopposed angiotensin II accumulation which further exacerbate tissue injury and promote both inflammation and thrombosis. The aim of the study is to evaluate the impact of circulating MPs on ACE2 expression, the cell-entry receptor for SARS-Cov2 on endothelial cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

NCT04884477

COVID-19 Immunosuppressed Host Convalescent Plasma +1 more

COMPLETED

Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients

NCT04475120

Covid19

COMPLETED PHASE2/PHASE3

Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19

NCT04385186

Infections, Coronavirus

UNKNOWN PHASE2

Convalescent Plasma Therapy - Zurich Protocol

NCT04869072

COVID-19

COMPLETED PHASE1

Inhaled Heparin for Hospitalised COVID-19 Patients

NCT04635241

Covid19

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Circulating MPs will be isolated from Covid-19 patients with lupus anticoagulant, from coronary artery diseases patients and from healthy volunteers without cardiovascular risk factors. Quantification of MPs will be realized by prothrombinase assay. Primary endothelial cells (ECs) from porcine coronary artery or porcine pulmonary artery will be isolated and cultured. ECs will be exposed to circulating MPs. Phenotypical changes (ACE2 expression, cytoadhesins, cytokines, tissue factor expression) of ECs will be examined. Susceptibility of ECs to SARS-COV-2 infection will be determined.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Covid-19 patients

Blood sample

Intervention Type OTHER

20 Ml blood sample

patients with coronary artery disease

Blood sample

Intervention Type OTHER

20 Ml blood sample

healthy volunteers

Blood sample

Intervention Type OTHER

20 Ml blood sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

20 Ml blood sample

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COVID-19 patients: age \> 18 yr
* SARS-COV-2 infection within 12 months and positive lupus anticoagulant
* Patients with cardiovascular risk factors: at least among
* Hypertension, Dyslipidemia, Diabetes mellitus, obesity, smoker, Healthy volunteers